Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI)

About Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI)

The Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) brings together leading experts in airway immunology and vaccine development to tackle some of the deadliest respiratory pathogens. The aim is to revolutionize and accelerate vaccine development by bridging the gap between academic research and industry innovation. NIVI is a partnership between the University of Copenhagen and the Novo Nordisk Foundation. The initiative is comprised of two distinct entities: NIVI Research Center is a state-of-the-art academic research center anchored at the Department of Immunology and Microbiology at the University of Copenhagen. NIVI-R directs the research, discovery and educational aspects of the NIVI initiative. For more information: https://niviresearch.ku.dk/about-center/ NIVI Development is a limited liability company owned by the Novo Nordisk Foundation. NIVI-D facilitates the initiatives translational efforts by providing industry-level expertise in vaccine development and clinical testing. NIVI’s VISION & MISSION Vision: To prevent airborne epidemics and limit the spread of anti-microbial resistance through the development of novel vaccines. Mission: To generate knowledge on host immunity, host-pathogen interactions, and vaccine technologies. And to translate this knowledge into vaccines that provide robust, durable and broad immunity against respiratory pathogens.